FDA Advisory Committee recommends ocriplasmin(Thrombogenics) for treatment of Vitreomacular Adhesions

ThromboGenics NV announced that the FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion (VMA). The Committee voted 10 to 0 at its meeting that the benefits of administering ocriplasmin for the treatment of vitreomacular adhesions outweigh the potential risks.Symptomatic VMA is a progressive condition that if left untreated frequently leads to retinal distortion, further deterioration in vision and has the potential to cause irreversible damage and complications. If approved, ocriplasmin will be the first pharmacological treatment for symptomatic VMA.